Zydus Ahmedabad Facility Receives One Observation Following USFDA cGMP Inspection

The United States Food and Drug Administration (USFDA) has completed a current Good Manufacturing Practices (cGMP) inspection at Zydus Lifesciences’ manufacturing facility located in SEZ II, Ahmedabad. The inspection, which lasted eight days from September 21 to September 28, resulted in one observation being issued by the US regulatory authority.

According to information shared by Zydus Lifesciences, the inspection focused on the company’s manufacturing operations at the Ahmedabad facility. At the conclusion of the inspection, the USFDA recorded a single observation. The company has stated that it will work with the regulator to address the matter and take appropriate action within the required timeframe.

An important aspect of the inspection outcome was the absence of any observations concerning data integrity. Data integrity remains a key area of regulatory attention in pharmaceutical manufacturing, particularly in relation to the reliability, accuracy and completeness of records and information generated during manufacturing and quality-control activities.

The company has not disclosed the specific nature of the observation raised by the USFDA. As a result, details regarding the particular manufacturing process, documentation, equipment or quality-system area associated with the observation are not currently available.

USFDA inspections of pharmaceutical manufacturing facilities form an important part of the regulatory oversight process for products intended for the US market. Such inspections assess whether manufacturing operations and associated quality systems comply with applicable cGMP requirements.

Zydus Lifesciences said it remains committed to working closely with the USFDA to resolve the observation. The inspection outcome relates specifically to the SEZ II manufacturing facility in Ahmedabad.

30-09-2026